logo
5 Ways We Can Improve Men's Mental Health in Business

5 Ways We Can Improve Men's Mental Health in Business

Entrepreneur4 hours ago

There are subtle ways businesses can improve the well-being of men who face the highest risk of poor mental health. Here's what you need to know.
Opinions expressed by Entrepreneur contributors are their own.
Men's mental health is in crisis worldwide. Statistics show that men account for 70% of suicides worldwide, as described in an article by Rob Whitley, a professor in psychiatry from McGill University in Canada. Despite this alarming fact, men are less likely than women to seek help when experiencing poor mental health. This is due to the fact that there is still a social stigma that makes many men believe that being perceived as vulnerable or seeking help goes against the norms of societal constructions of masculinity.
Interestingly, research by Mind, a UK mental health charity, found that work life is the main source of men's mental health issues. The charity found that one in three men attribute work stress to the ill effects on their mental wellbeing, which is twice as many as women who report this. According to another study conducted by CV Library in 2019, 61% of men surveyed wanted to quit their work as it affected their mental health, compared to only 48.5% of women who said so.
Moreover, the pressure to perform well in business has meant that CEOs and entrepreneurs are disproportionately affected by mental health issues, too, compared to the wider public, according to an article published in Small Business Economics.
Related: Taking Care of Mental Health Is Powerful, Not Weak
When the Priory Group, a mental healthcare facilities provider in the UK, interviewed 1,000 men for a survey on men's mental health, they discovered that although 60% of men have talked about their mental health with someone at some point in their lives, 40% of men still haven't discussed their mental health issues with close friends, family or even a medical professional. Among these men who have never opened up about their mental health, the majority reported that the underlying reason for it is that they'd learned to deal with it themselves, with the second and third most popular reasons being, "I don't wish to be a burden to anyone" and "I'm too embarrassed."
These findings tell me that there is a way forward, but it requires out-of-the-box thinking. To tackle men's mental health in business, we need to craft solutions that will make men more likely to seek help in their workspaces, without feeling embarrassed about it. Here are five ways we can do this:
1. Bringing awareness to the workplace
One of the first steps to destigmatizing the shame many men face with regard to mental health issues is to normalize the discourse around mental health issues. According to an independent workplace mental health review by Lord Dennis Stevenson and Paul Farmer conducted in 2017, "the correct way to view mental health is that we all have it and we fluctuate between thriving, struggling and being ill and possibly off work." Bringing the realization that even a seemingly healthy and productive employee or business leader can have underlying mental health issues will lessen the pressures many men face around seeking help.
Through normalizing these discussions via newsletters, group projects and even casual training sessions, a workplace can be an easier space for men to discuss their mental health challenges if the subject matter is actively framed as something that everyone collectively could go through.
Related: 6 Common Barriers to Happiness and Productivity for Men
2. Reduce the usage of the term "mental health"
To ensure that mental health services in the workplace are utilized by men, it is vital that we change the language we use to describe the problem in the first place. Using the term "mental health" can be distressing or off-putting for men, according to research, and instead, more specific terms such as "stress" or "burnout" should be used to describe mental health problems.
Men prefer focusing on and talking about problems that are more solvable, so avoiding broader terms when discussing mental health issues can make them open up more. Asking men specific questions relating to work performance could be easier for them to tackle instead of asking more general questions like, "Are you okay?"
3. Encourage lifestyle-based solutions
Men can often feel isolated if they are identified as having a personal problem in their workplace. Instead, greater benefits could be achieved in men's mental health when mental health solutions are tied to wider lifestyle solutions, creating workplace activities that carry out themes such as sportsmanship, camaraderie and teamwork. Making mental health something that a company can work together to improve will make men's participation more likely, since the focus is not entirely on them as individuals.
Well-being outings, group mentorships and friendly sporting events could be promoted as activities that could improve the collective well-being of a workplace and help colleagues work together collaboratively. According to the mental health charity Mind's "Get It Off Your Chest" study, men have a high preference for physical activities when it comes to tackling their mental health.
4. Provide access to online therapy
Research has found that men are more likely to seek help when they can consult a mental health professional, especially when this can be done online, where anonymity can be guaranteed. This approach would also ensure that men would be confident to discuss their mental health struggles without feeling like they're putting their job or position at the company at risk.
Related: We Need a Real Commitment to Mental Health at Work. Here's How (and Why).
5. Create good senior role models
Men are more likely to be empowered to take care of themselves and others when other men in leadership positions are seen to be doing the same. It can be very powerful, for instance, for a male CEO or senior executive to talk to their employees about their own mental health struggles and explain how they work towards their mental well-being. The same could be said about the CEO and entrepreneurial communities, where businesses can work together to ensure that their leaders can work collaboratively and share personal experiences to improve their mental health and well-being together.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Ricotta Is The Most Underrated High-Protein Cheese
Ricotta Is The Most Underrated High-Protein Cheese

Vogue

time36 minutes ago

  • Vogue

Ricotta Is The Most Underrated High-Protein Cheese

There are so many varieties of ricotta cheese: it can be made from cow, sheep, goat, or buffalo milk, and is available in salted, baked, and smoked versions. Delicious and versatile, it's also an incredibly underrated health food. When you consider the nutritional properties of ricotta, you'll find that it's one of the healthiest cheeses you can eat, right up there with the ever-popular and high-protein cottage cheese. What is ricotta? Believe it or not, ricotta doesn't technically count as a cheese. It's actually a dairy byproduct that's been eaten since the Bronze Age, and is made from whey—the liquid that remains after making other cheeses. Makers will then heat the whey and add acid, which causes flakes to form on the surface. These flakes are ricotta. Mild in taste, ricotta is typically light, with a creamy texture. Why is ricotta a healthy choice? According to the British Heart Foundation, ricotta is low in salt and fat, with only 10% fat, of which six percent is saturated. The protein content will depend on whether it's made with whole milk, semi-skimmed milk, or is low-fat, but typically, in 100g, you'll get: 7 to 8g of protein in whole milk ricotta 8 to 9g of protein in semi-skimmed-milk ricotta 10 to 11g of protein in low-fat or fat-free ricotta Plus, ricotta contains a plethora of vitamins and minerals, including vitamin K and calcium, both of which are beneficial for bone health and blood clotting. The benefits of eating ricotta cheese It's easily digestible It has a low-glycemic index, meaning it won't spike your blood sugar It contains little fat compared to other fresh cheeses like feta, mozzarella, and mascarpone It's low in calories (140 calories per 100g) It's rich in protein, which can help with muscle building and recovery It's beneficial for bone health thanks to the calcium and vitamin K It's rich in vitamin B 12 , which supports a healthy metabolism, red blood cell formation, and good nervous system health , which supports a healthy metabolism, red blood cell formation, and good nervous system health Due to the high-protein content, it's a satiating food to eat Because ricotta contains both whey protein and phosphorus, it can help in regulating blood pressure Is there anyone who should avoid eating ricotta? Unless you've been told by your doctor to avoid eating food with the nutritional profile of ricotta, there's only one group who should avoid it: those with lactose intolerance. Even though ricotta is a dairy byproduct, it still contains lactose and therefore wouldn't be appropriate for those with intolerances or allergies. 6 ways to eat ricotta Spoon fresh ricotta into a bowl and top with berries, fresh fruit, and nuts for a satiating, high-protein breakfast. Mix ricotta with oats and a little milk/water and leave to soak overnight. Add chopped fresh fruit and coconut flakes in the morning for a delicious, protein-rich overnight oats breakfast. For an easy dessert, drizzle honey or maple syrup, with a sprinkling of cinnamon, over a small bowl of ricotta. Make a protein mousse by blending ricotta with cocoa and a couple of dates. Spread on sourdough, rice cakes, or corn cakes and top with a little extra virgin olive oil, salt, pepper, and cherry tomatoes. Use in homemade pasta sauces, like the recipe below. Ricotta and sun-dried tomato pasta Serves: 2

Spironolactone Offers No CV Benefit in Dialysis Patients
Spironolactone Offers No CV Benefit in Dialysis Patients

Medscape

time2 hours ago

  • Medscape

Spironolactone Offers No CV Benefit in Dialysis Patients

VIENNA — Spironolactone, a mineralocorticoid receptor antagonist (MRA), does not reduce the rates of cardiovascular (CV) death or heart failure in patients undergoing maintenance dialysis, according to ACHIEVE trial results. In addition, the relatively high rates of hyperkalemia associated with the drug — despite a run-in period — limit its use, said lead investigator Michael Walsh, MD, PhD, Renal Research Program, Population Health Research Institute, Hamilton, Ontario, Canada, who presented the results at the 62nd European Renal Association Congress on June 6. He added: 'Cardiovascular mortality remains very high' in these patients, at the 'somewhat astounding' rate of 11% per year in the current trial. The ACHIEVE Trial Previous trials have suggested that MRAs are perhaps the 'most promising therapies' in this space, Walsh noted. He and his colleagues undertook the Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease (ACHIEVE) trial to evaluate the efficacy and safety of spironolactone. The study included patients (age, ≥ 45 y or ≥ 18 y with history of diabetes) with kidney failure receiving maintenance dialysis who were at risk of CV death. All patients underwent an active run-in where they were prescribed open-label spironolactone 25 mg/day for at least 7 weeks with no dosing adjustments followed by a final eligibility assessment to ensure they were ≥ 80% adherent to the medication and that their serum potassium levels did not exceed 6.0 mmol/L. After the run-in period, 2538 of the originally selected 3565 patients were randomized to either spironolactone 25 mg/day or matching placebo. Follow-up was at 3 months, 6 months, and then every 6 months after, assessing for outcomes, safety, drug adherence, and drug resupply. Unlike the run-in period, clinicians could reduce the dose to 25 mg/three times a week if appropriate. The average age of the patients was approximately 62 years, roughly 37% were female, and the median time that the patients had been receiving dialysis was 2 years. The primary cause of kidney failure was diabetes, in just over 40% of patients, followed by hypertension/ischemia in slightly over 25%. The trial was stopped early by the external safety and event monitoring committee for futility, meaning it did not reach the target number events, even after the target had been revised downward due to better-than-expected adherence. Walsh stated that the trial did not reach its primary outcome, with no significant difference in rates of CV death or heart failure hospitalization between the spironolactone and placebo groups at a hazard ratio (HR) of 0.92 ( P = .35). There was also no significant difference between the two treatments when stratifying the patients by sex, previous heart failure, previous coronary artery disease, and the length of time they had been receiving dialysis. Further analysis indicated there was no benefit from spironolactone over placebo when looking at cardiac and vascular deaths separately and when considering first and total heart failure hospitalizations individually. However, spironolactone was associated with an increased risk of hyperkalemia, with 123 events in the spironolactone-treated group vs 80 in the placebo group (HR, 1.54; 95% CI, 1.07-2.22). Walsh noted that, despite the strengths of its large size and the high rates of adherence, the trial is limited by having a low statistical power due to being stopped early, the use of a composite primary outcome, and the challenge in defining the patients most likely to benefit from the intervention. Important Clinical Question Session co-Chair Ronald T. Gansevoort, MD, PhD, professor of medicine and a nephrologist at the Department of Nephrology, University Medical Center Groningen, Netherlands, told Medscape Medical News that the study addressed an 'important clinical question,' and it is 'a pity that it didn't work out.' He noted there have been numerous studies of CV disease in patients with chronic kidney disease who are not on dialysis, but 'there have been so few trials in dialysis patients,' and there consequently remains a lot to learn in this space. As to what the current findings mean for MRAs in general in preventing CV outcomes, Gansevoort said he is 'not sure, because there are drug-specific differences between the first, second, and third generation, and we cannot extrapolate the findings with the first generation to the third.' 'Whether there ever will be a trial with the third generation in dialysis patients, I doubt, because industry will not want to fund it,' he continued, and so it will 'remain an important question.' Christoph Wanner, MD, PhD, professor of medicine and head of the Division of Nephrology, University of Würzburg, Germany, noted that even if the number of patients in the trial were increased to 4000 or 5000 it would still not 'resolve the issue.' 'I think it's the end for MRAs in dialysis,' he told Medscape Medical News , and 'we have to think about what's going wrong in dialysis patients.' 'We started with statins. They didn't work. Hemodialysis/ hemodiafiltration does work, but drugs do not work. Why is this the case? What's going on? Did we design the right trials?' Wanner continued, 'I think this is still a [relevant research] question, but at the moment, with the ACHIEVE trial, the story of MRAs in dialysis is coming to an end.' 'Everyone who deals with dialysis patients realizes there is an excess of mortality, despite advancements in the technology of dialysis over the last 50 years,' noted Walsh at the start of his presentation. He continued that there have been reductions in deaths from atheromatous CV disease among patients receiving dialysis for kidney failure, but 'importantly, the other kinds of reasons, including non-atheromatous cardiovascular disease, remain extremely high,' accounting for approximately 40% of all deaths in these patients. 'Trying to understand why there is such a high risk of cardiovascular death has been challenging,' Walsh added. ACHIEVE was funded by grants from the Canadian Institutes of Health Research (Canada), the Medical Research Future Fund (Australia), the Health Research Council (New Zealand), the British Heart Foundation (United Kingdom), the Population Health Research Institute (Canada), St. Joseph's Healthcare Hamilton Division of Nephrology (Canada), Accelerating Clinical Trials (Canada), the CanSOLVE CKD Network (Canada), and the Department of Medicine, Dalhousie University (Canada). No relevant financial relationships declared.

NHS Blood Supplies Running Low Amid Donor Shortage
NHS Blood Supplies Running Low Amid Donor Shortage

Medscape

time2 hours ago

  • Medscape

NHS Blood Supplies Running Low Amid Donor Shortage

NHS Blood and Transplant (NHSBT) has issued an urgent call for more blood donors 'to stabilise the nation's blood supply', warning that stocks of O negative red cells are nearing red alert status. NHSBT said there was an annual shortfall of 200,000 donors needed to meet growing demand. Dr Jo Farrar, the body's chief executive, said that maintaining stocks over the past 12 months had been 'challenging'. Cyber-Attack Led to Acute Shortage The supply problem was exacerbated by last summer's ransomware attack on several London hospitals. The disruption to cross-matching procedures forced clinicians to rely on O negative blood. This blood type is known as the 'universal donor' because it can be given to patients of any blood group without triggering a transfusion reaction. Just 8% of the population has O negative blood but it accounts for 16% of hospital demand. As the ransomware threat unfolded, NHSBT shut down multiple IT systems as a precautionary measure. This led to major disruptions in blood collection and transport. Several London hospitals declared critical incidents, cancelled surgeries and tests, and faced transfusion delays. Blood Stocks Remain Critically Low NHSBT said stocks have yet to recover, with current levels strained by a recent series of bank holidays falling in quick succession. NHSBT aims to maintain 6 days' stock of red blood cells. As of 9 am on 9 June, supplies of O-, B-, AB-, O+, and A+ all fell below that threshold, with O- at just 3.4 days. Only A-, B+, and AB+ blood types registered more than 6 days of stock. A letter sent to senior managers and practitioners on 21 May warned that the ongoing amber alert for group O red cells could escalate to a red alert. A pre-amber alert remains in place for group B D-negative red cells. The letter urged adherence to the National Blood Transfusion Committee's red cell shortage plan which was updated in October 2024. Call for One Million Active Donors To meet NHS demand safely, NHSBT said it needs one million regular blood donors. However, its most recent analysis showed participation fell short by over 200,000. Despite an increase in new donor registrations over the past year, only 24% of registrants went on to give blood. Currently, just 2% of the population is supporting the country's blood supply. In support of National Blood Week (9-15 June), NHSBT urged people to join 'the country's largest volunteering force' by donating blood. Focus on Donors with Ro Subtype NHSBT highlighted a critical need for more donors of Black Caribbean and Black African heritage. Around half of people in these groups have the Ro subtype, vital for treating sickle cell disease, the UK's fastest growing genetic blood disorder. In a press release, Health Minister Baroness Merron said: 'The NHS is in urgent need of more lifesaving blood donors from all backgrounds. We are working alongside NHSBT to make donating blood easier than ever before, opening up new donor centres and making appointments available closer to home.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store